A detailed history of Palo Alto Investors LP transactions in Novo Cure LTD stock. As of the latest transaction made, Palo Alto Investors LP holds 561,908 shares of NVCR stock, worth $9.63 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares
561,908
Previous 561,908 -0.0%
Holding current value
$9.63 Million
Previous $8.39 Million 4.68%
% of portfolio
1.03%
Previous 0.77%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$11.13 - $15.78 $1.09 Million - $1.55 Million
-98,367 Reduced 14.9%
561,908 $8.39 Million
Q3 2023

Nov 14, 2023

BUY
$16.15 - $42.35 $1.33 Million - $3.48 Million
82,157 Added 14.21%
660,275 $10.7 Million
Q2 2023

Aug 14, 2023

BUY
$40.29 - $82.51 $22 Million - $45 Million
545,328 Added 1663.09%
578,118 $24 Million
Q1 2023

May 15, 2023

BUY
$56.44 - $118.81 $1.85 Million - $3.9 Million
32,790 New
32,790 $1.97 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.8B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Palo Alto Investors LP Portfolio

Follow Palo Alto Investors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.